Ok, yes there are 3 arms, but realistically we're looking at 2.
The 3 arms are:
1. SOC + Placebo
2. SOC + Multikine alone
3. SOC + Multikine + CIZ.
For clarification CIZ:
C = Cyclophosphamide (is a chemotherapy agent and to suppress the immune system)
I = Indomethacin (is an NSAID pain-killer)
z = Zinc (improves cell mediated immune functions and is an antioxidant and anti-inflammatory agent)
CIZ combination are basic and can be used as neo-adjuvent treatments that may be part of pre-surgery SOC but do not work in curing cancer, but are hopefully will help in the main treatment, but well these can't hurt so why not.
Therefore realistically we are looking at two arms which are Multikine. They only have the distinction between CIZ and not CIZ to work out the exact effect from Multikine.
So yes if the distribution is as mentioned which I had not understoof before 3/7, 3/7, 1/7.
Then ok, we therefore have 795 patients on SOC + Multikine (again Multikine + CIZ is basically the same as just Multikine), and 132 on Placebo.
Fact is that given the 5 year survival we would be expecting 344 event by May 2018 if Multikine were just as effective as SOC. But as we have not yet reached the 298 mark this would indicate benefit from Multikine.
Do you disagree with the above?
News 
Market Data 
Discover 
